Logo image of ARTL

ARTELO BIOSCIENCES INC (ARTL) Stock Overview

USA - NASDAQ:ARTL - US04301G6070 - Common Stock

4.19 USD
+0.18 (+4.49%)
Last: 10/17/2025, 8:00:01 PM
4.08 USD
-0.11 (-2.63%)
After Hours: 10/17/2025, 8:00:01 PM

ARTL Key Statistics, Chart & Performance

Key Statistics
Market Cap8.38M
Revenue(TTM)N/A
Net Income(TTM)-10503000
Shares2.00M
Float1.84M
52 Week High28.6
52 Week Low3.91
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-19.05
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO2015-10-13
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ARTL short term performance overview.The bars show the price performance of ARTL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

ARTL long term performance overview.The bars show the price performance of ARTL in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of ARTL is 4.19 USD. In the past month the price decreased by -25.44%. In the past year, price decreased by -39.28%.

ARTELO BIOSCIENCES INC / ARTL Daily stock chart

ARTL Latest News, Press Relases and Analysis

ARTL Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 49.71 759.85B
JNJ JOHNSON & JOHNSON 18.61 465.34B
AZN ASTRAZENECA PLC-SPONS ADR 19.07 262.58B
NVS NOVARTIS AG-SPONSORED ADR 14.85 254.43B
NVO NOVO-NORDISK A/S-SPONS ADR 13.98 241.59B
MRK MERCK & CO. INC. 11.01 211.79B
PFE PFIZER INC 7.23 139.35B
SNY SANOFI-ADR 11.43 123.36B
BMY BRISTOL-MYERS SQUIBB CO 6.48 88.81B
GSK GSK PLC-SPON ADR 9.74 88.32B
ZTS ZOETIS INC 23.16 63.84B
TAK TAKEDA PHARMACEUTIC-SP ADR 48.41 44.34B

About ARTL

Company Profile

ARTL logo image Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 5 full-time employees. The company went IPO on 2015-10-13. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Company Info

ARTELO BIOSCIENCES INC

505 Lomas Santa Fe, Suite 160

Solana Beach CALIFORNIA 92037 US

CEO: Gregory D. Gorgas

Employees: 5

ARTL Company Website

ARTL Investor Relations

Phone: 18589257049

ARTELO BIOSCIENCES INC / ARTL FAQ

What is the stock price of ARTELO BIOSCIENCES INC today?

The current stock price of ARTL is 4.19 USD. The price increased by 4.49% in the last trading session.


What is the ticker symbol for ARTELO BIOSCIENCES INC stock?

The exchange symbol of ARTELO BIOSCIENCES INC is ARTL and it is listed on the Nasdaq exchange.


On which exchange is ARTL stock listed?

ARTL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ARTELO BIOSCIENCES INC stock?

8 analysts have analysed ARTL and the average price target is 30.6 USD. This implies a price increase of 630.31% is expected in the next year compared to the current price of 4.19. Check the ARTELO BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARTELO BIOSCIENCES INC worth?

ARTELO BIOSCIENCES INC (ARTL) has a market capitalization of 8.38M USD. This makes ARTL a Nano Cap stock.


How many employees does ARTELO BIOSCIENCES INC have?

ARTELO BIOSCIENCES INC (ARTL) currently has 5 employees.


What are the support and resistance levels for ARTELO BIOSCIENCES INC (ARTL) stock?

ARTELO BIOSCIENCES INC (ARTL) has a resistance level at 4.35. Check the full technical report for a detailed analysis of ARTL support and resistance levels.


Should I buy ARTELO BIOSCIENCES INC (ARTL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARTELO BIOSCIENCES INC (ARTL) stock pay dividends?

ARTL does not pay a dividend.


When does ARTELO BIOSCIENCES INC (ARTL) report earnings?

ARTELO BIOSCIENCES INC (ARTL) will report earnings on 2025-11-10.


What is the Price/Earnings (PE) ratio of ARTELO BIOSCIENCES INC (ARTL)?

ARTELO BIOSCIENCES INC (ARTL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-19.05).


What is the Short Interest ratio of ARTELO BIOSCIENCES INC (ARTL) stock?

The outstanding short interest for ARTELO BIOSCIENCES INC (ARTL) is 3.03% of its float. Check the ownership tab for more information on the ARTL short interest.


ARTL Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ARTL Financial Highlights

Over the last trailing twelve months ARTL reported a non-GAAP Earnings per Share(EPS) of -19.05. The EPS increased by 6.62% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -241.06%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-24.67%
Sales Q2Q%N/A
EPS 1Y (TTM)6.62%
Revenue 1Y (TTM)N/A

ARTL Forecast & Estimates

8 analysts have analysed ARTL and the average price target is 30.6 USD. This implies a price increase of 630.31% is expected in the next year compared to the current price of 4.19.


Analysts
Analysts80
Price Target30.6 (630.31%)
EPS Next Y58.98%
Revenue Next YearN/A

ARTL Ownership

Ownership
Inst Owners1.51%
Ins Owners0.32%
Short Float %3.03%
Short Ratio0.34